{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T20:06:15Z","timestamp":1776283575609,"version":"3.50.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,8]],"date-time":"2024-06-08T00:00:00Z","timestamp":1717804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Pheochromocytoma is a rare neuroendocrine tumor. Despite the low incidence, these tumors are of indisputable importance. This study aimed to analyze the management of pheochromocytoma in a referral center, with an emphasis on the minimally invasive adrenalectomy, which is the preferred therapeutic approach.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A retrospective analysis was performed on a cohort of patients diagnosed with pheochromocytoma who underwent adrenalectomy between January 2013 and December 2022. Clinical data including demographics, timelines, symptomatology, comorbidities, biochemical markers, genetic testing, surgical details, and follow-up outcomes, were collected and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The cohort included 44 patients, predominantly women (52.27%), with a median age of 53.39 years (range 13\u201383). Most of patients exhibited paroxysmal symptoms suggesting catecholamine excess. Documented hypertension was the most frequent (86.36%), along with glucose anomalies (40.01%) and anxiety disorder (31.82%). Genetic testing was performed in 36 (81.81%) patients and 14 (38.88%) revealed a positive result, predominantly\n                      <jats:italic>RET<\/jats:italic>\n                      pathogenic variant. Laparoscopic surgery was performed in 34 (79.07%) patients, showing significantly shorter operative time (2.5\u2009h vs. 4.25\u2009h, t-test p\u2009&lt;\u20090,001) and fewer complications (23.53% vs 77.78%, p\u2009=\u20090.008). Postoperative complications occurred in 36.36% of the patients, mostly mild (grade I, 56.25%), with no mortality.\n                      <jats:italic>SDHB<\/jats:italic>\n                      pathogenic variant correlated with both recurrent and metastatic disease (p\u2009=\u20090.006). One-year follow-up reported 9.09% recurrence and 6.82% metastasis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Adrenalectomy demonstrated a high safety and effectiveness. This study exhibited a higher rate of genetic testing referral than other studies. Despite past advances, there is still a need for further studies to establish protocols and evaluate new techniques.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12020-024-03916-y","type":"journal-article","created":{"date-parts":[[2024,6,7]],"date-time":"2024-06-07T23:25:41Z","timestamp":1717802741000},"page":"409-416","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The role of the adrenalectomy in the management of pheochromocytoma: the experience of a Portuguese referral center"],"prefix":"10.1007","volume":"86","author":[{"given":"In\u00eas Costa","family":"Carvalho","sequence":"first","affiliation":[]},{"given":"Miguel V. B.","family":"Machado","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o P.","family":"Morais","sequence":"additional","affiliation":[]},{"given":"Filipa","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Elisabete","family":"Barbosa","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Barbosa","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2024,6,8]]},"reference":[{"key":"3916_CR1","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1515\/enr-2017-0018","volume":"51","author":"FA Farrugia","year":"2017","unstructured":"F.A. Farrugia, G. Martikos, P. Tzanetis, A. Charalampopoulos, E. Misiakos, N. Zavras et al. Pheochromocytoma, diagnosis and treatment: Review of the literature. Endocr. Regul. 51, 168\u2013181 (2017). https:\/\/doi.org\/10.1515\/enr-2017-0018","journal-title":"Endocr. Regul."},{"key":"3916_CR2","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1177\/0004563217739931","volume":"55","author":"AS Davison","year":"2018","unstructured":"A.S. Davison, D.M. Jones, S. Ruthven, T. Helliwell, S.L. Shore, Clinical evaluation and treatment of phaeochromocytoma. Ann. Clin. Biochem. 55, 34\u201348 (2018). https:\/\/doi.org\/10.1177\/0004563217739931","journal-title":"Ann. Clin. Biochem."},{"key":"3916_CR3","doi-asserted-by":"publisher","first-page":"101346","DOI":"10.1016\/j.beem.2019.101346","volume":"34","author":"E Sbardella","year":"2020","unstructured":"E. Sbardella, A.B. Grossman, Pheochromocytoma: An approach to diagnosis. Best Pract. Res. Clin. Endocrinol. Metab. 34, 101346 (2020). https:\/\/doi.org\/10.1016\/j.beem.2019.101346","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"3916_CR4","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1210\/jendso\/bvac105","volume":"6","author":"AR Al Subhi","year":"2022","unstructured":"A.R. Al Subhi, V. Boyle, M.S. Elston, Systematic review: Incidence of pheochromocytoma and paraganglioma over 70 years. J. Endocr. Soc. 6, 105 (2022). https:\/\/doi.org\/10.1210\/jendso\/bvac105","journal-title":"J. Endocr. Soc."},{"key":"3916_CR5","doi-asserted-by":"publisher","first-page":"2251","DOI":"10.1210\/clinem\/dgaa965","volume":"106","author":"A Ebbehoj","year":"2021","unstructured":"A. Ebbehoj, K. Stochholm, S.F. Jacobsen, C. Trolle, P. Jepsen, M.G. Robaczyk et al. Incidence and clinical presentation of pheochromocytoma and sympathetic paraganglioma: A population-based study. J. Clin. Endocrinol. Metab. 106, 2251 (2021). https:\/\/doi.org\/10.1210\/clinem\/dgaa965","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3916_CR6","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1007\/s12094-021-02622-9","volume":"23","author":"R Garcia-Carbonero","year":"2021","unstructured":"R. Garcia-Carbonero, F. Matute Teresa, E. Mercader-Cidoncha, M. Mitjavila-Casanovas, M. Robledo, I. Tena et al. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas. Clin. Transl. Oncol. 23, 1995\u20132019 (2021). https:\/\/doi.org\/10.1007\/s12094-021-02622-9","journal-title":"Clin. Transl. Oncol."},{"key":"3916_CR7","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1056\/NEJMra1806651","volume":"381","author":"HPH Neumann","year":"2019","unstructured":"H.P.H. Neumann, W.F. Young Jr., C. Eng, Pheochromocytoma and paraganglioma. N. Engl. J. Med. 381, 552\u2013565 (2019). https:\/\/doi.org\/10.1056\/NEJMra1806651","journal-title":"N. Engl. J. Med."},{"key":"3916_CR8","doi-asserted-by":"publisher","first-page":"2313","DOI":"10.1007\/s40618-022-01868-6","volume":"45","author":"Y Ando","year":"2022","unstructured":"Y. Ando, Y. Ono, A. Sano, N. Fujita, S. Ono, Y. Tanaka, Clinical characteristics and outcomes of pheochromocytoma crisis: a literature review of 200 cases. J. Endocrinol. Investig. 45, 2313\u20132328 (2022). https:\/\/doi.org\/10.1007\/s40618-022-01868-6","journal-title":"J. Endocrinol. Investig."},{"key":"3916_CR9","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejim.2018.01.015","volume":"51","author":"AMA Berends","year":"2018","unstructured":"A.M.A. Berends, E. Buitenwerf, R.R. de Krijger, N. Veeger, A.N.A. van der Horst-Schrivers, T.P. Links et al. Incidence of pheochromocytoma and sympathetic paraganglioma in the Netherlands: A nationwide study and systematic review. Eur. J. Intern. Med. 51, 68\u201373 (2018). https:\/\/doi.org\/10.1016\/j.ejim.2018.01.015","journal-title":"Eur. J. Intern. Med."},{"key":"3916_CR10","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1097\/HJH.0000000000002438","volume":"38","author":"JWM Lenders","year":"2020","unstructured":"J.W.M. Lenders, M.N. Kerstens, L. Amar, A. Prejbisz, M. Robledo, D. Taieb et al. Genetics, diagnosis, management and future directions of research of phaeochromocytoma and paraganglioma: A position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 38, 1443\u20131456 (2020). https:\/\/doi.org\/10.1097\/HJH.0000000000002438","journal-title":"J. Hypertens."},{"key":"3916_CR11","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1210\/endrev\/bnab019","volume":"43","author":"S N\u00f6lting","year":"2022","unstructured":"S. N\u00f6lting, N. Bechmann, D. Taieb, F. Beuschlein, M. Fassnacht, M. Kroiss et al. Personalized management of pheochromocytoma and paraganglioma. Endocr. Rev. 43, 199\u2013239 (2022). https:\/\/doi.org\/10.1210\/endrev\/bnab019","journal-title":"Endocr. Rev."},{"key":"3916_CR12","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1530\/ERC-19-0024","volume":"26","author":"J Crona","year":"2019","unstructured":"J. Crona, A. Lamarca, S. Ghosal, S. Welin, B. Skogseid, K. Pacak, Genotype-phenotype correlations in pheochromocytoma and paraganglioma: A systematic review and individual patient meta-analysis. Endocr. Relat. Cancer 26, 539\u2013550 (2019). https:\/\/doi.org\/10.1530\/ERC-19-0024","journal-title":"Endocr. Relat. Cancer"},{"key":"3916_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.3803\/EnM.2020.925","volume":"36","author":"J Ahn","year":"2021","unstructured":"J. Ahn, J.Y. Park, G. Kim, S.M. Jin, K.Y. Hur, S.Y. Lee et al. Urinary free metanephrines for diagnosis of pheochromocytoma and paraganglioma. Endocrinol. Metab. 36, 697\u2013701 (2021). https:\/\/doi.org\/10.3803\/EnM.2020.925","journal-title":"Endocrinol. Metab."},{"key":"3916_CR14","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1373\/clinchem.2018.291369","volume":"64","author":"G Eisenhofer","year":"2018","unstructured":"G. Eisenhofer, A. Prejbisz, M. Peitzsch, C. Pamporaki, J. Masjkur, N. Rogowski-Lehmann et al. Biochemical diagnosis of Chromaffin cell tumors in patients at high and low risk of disease: Plasma versus urinary free or deconjugated o-methylated catecholamine metabolites. Clin. Chem. 64, 1646\u20131656 (2018). https:\/\/doi.org\/10.1373\/clinchem.2018.291369","journal-title":"Clin. Chem."},{"key":"3916_CR15","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1007\/s00423-019-01768-z","volume":"404","author":"K Lorenz","year":"2019","unstructured":"K. Lorenz, P. Langer, B. Niederle, P. Alesina, K. Holzer, C. Nies et al. Surgical therapy of adrenal tumors: Guidelines from the German Association of Endocrine Surgeons (CAEK). Langenbecks Arch. Surg. 404, 385\u2013401 (2019). https:\/\/doi.org\/10.1007\/s00423-019-01768-z","journal-title":"Langenbecks Arch. Surg."},{"key":"3916_CR16","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1530\/EJE-16-0189","volume":"175","author":"L Amar","year":"2016","unstructured":"L. Amar, C. Lussey-Lepoutre, J.W. Lenders, J. Djadi-Prat, P.F. Plouin, O. Steichen, Management of endocrine disease: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: A systematic review and meta-analysis. Eur. J. Endocrinol. 175, 135\u201345 (2016). https:\/\/doi.org\/10.1530\/EJE-16-0189","journal-title":"Eur. J. Endocrinol."},{"key":"3916_CR17","doi-asserted-by":"publisher","first-page":"1050","DOI":"10.1002\/cncr.31916","volume":"125","author":"T Chandrasekar","year":"2019","unstructured":"T. Chandrasekar, H. Goldberg, Z. Klaassen, C.J.D. Wallis, D.T.S. Woon, J.O. Herrera-Caceres et al. The who, when, and why of primary adrenal malignancies: Insights into the epidemiology of a rare clinical entity. Cancer 125, 1050\u20131059 (2019). https:\/\/doi.org\/10.1002\/cncr.31916","journal-title":"Cancer"},{"key":"3916_CR18","doi-asserted-by":"publisher","first-page":"1386","DOI":"10.1210\/jc.2018-01707","volume":"104","author":"LM Gruber","year":"2019","unstructured":"L.M. Gruber, R.P. Hartman, G.B. Thompson, T.J. McKenzie, M.L. Lyden, B.M. Dy et al. Pheochromocytoma characteristics and behavior differ depending on method of discovery. J. Clin. Endocrinol. Metab. 104, 1386\u20131393 (2019). https:\/\/doi.org\/10.1210\/jc.2018-01707","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3916_CR19","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s12020-017-1310-9","volume":"59","author":"E Sbardella","year":"2018","unstructured":"E. Sbardella, T. Cranston, A.M. Isidori, B. Shine, A. Pal, B. Jafar-Mohammadi et al. Routine genetic screening with a multi-gene panel in patients with pheochromocytomas. Endocrine 59, 175\u2013182 (2018). https:\/\/doi.org\/10.1007\/s12020-017-1310-9","journal-title":"Endocrine"},{"key":"3916_CR20","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40200-016-0226-x","volume":"15","author":"A Soltani","year":"2015","unstructured":"A. Soltani, M. Pourian, B.M. Davani, Does this patient have Pheochromocytoma? A systematic review of clinical signs and symptoms. J. Diabetes Metab. Disord. 15, 6 (2015). https:\/\/doi.org\/10.1186\/s40200-016-0226-x","journal-title":"J. Diabetes Metab. Disord."},{"key":"3916_CR21","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/S0140-6736(05)67139-5","volume":"366","author":"JW Lenders","year":"2005","unstructured":"J.W. Lenders, G. Eisenhofer, M. Mannelli, K. Pacak, Phaeochromocytoma. Lancet 366, 665\u201375 (2005). https:\/\/doi.org\/10.1016\/S0140-6736(05)67139-5","journal-title":"Lancet"},{"key":"3916_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.2478\/enr-2021-0003","volume":"55","author":"NA Soares","year":"2021","unstructured":"N.A. Soares, M. Pacheco, M. de Sousa, M.L. Matos, S.A.L. Ferreira, Pheochromocytoma: A retrospective study from a single center. Endocr. Regul. 55, 16\u201321 (2021). https:\/\/doi.org\/10.2478\/enr-2021-0003","journal-title":"Endocr. Regul."},{"key":"3916_CR23","doi-asserted-by":"publisher","first-page":"24335","DOI":"10.1097\/MD.0000000000024335","volume":"100","author":"S Jia","year":"2021","unstructured":"S. Jia, C. Li, Z. Lei, Q. Xia, Y. Jiang, Determinants of anxiety and depression among pheochromocytoma patients: A case-control study. Medicine 100, 24335 (2021). https:\/\/doi.org\/10.1097\/MD.0000000000024335","journal-title":"Medicine"},{"key":"3916_CR24","doi-asserted-by":"publisher","first-page":"2118","DOI":"10.1038\/s41386-018-0024-x","volume":"43","author":"YS Mineur","year":"2018","unstructured":"Y.S. Mineur, E.L. Cahuzac, T.N. Mose, M.P. Bentham, M.E. Plantenga, D.C. Thompson et al. Interaction between noradrenergic and cholinergic signaling in amygdala regulates anxiety- and depression-related behaviors in mice. Neuropsychopharmacology 43, 2118\u20132125 (2018). https:\/\/doi.org\/10.1038\/s41386-018-0024-x","journal-title":"Neuropsychopharmacology"},{"key":"3916_CR25","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1530\/ERC-22-0218","volume":"29","author":"M Araujo-Castro","year":"2022","unstructured":"M. Araujo-Castro, C. M\u00ednguez Ojeda, R. Garc\u00eda Centeno, M.C. L\u00f3pez-Garc\u00eda, C. Lamas, F.A. Hanzu et al. Glycemic disorders in patients with pheochromocytomas and sympathetic paragangliomas. Endocr. Relat. Cancer 29, 645\u2013655 (2022). https:\/\/doi.org\/10.1530\/ERC-22-0218","journal-title":"Endocr. Relat. Cancer"},{"key":"3916_CR26","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.ando.2020.01.001","volume":"81","author":"A Elenkova","year":"2020","unstructured":"A. Elenkova, J. Matrozova, V. Vasilev, R. Robeva, S. Zacharieva, Prevalence and progression of carbohydrate disorders in patients with pheochromocytoma\/paraganglioma: retrospective single-center study. Ann. Endocrinol. 81, 3\u201310 (2020). https:\/\/doi.org\/10.1016\/j.ando.2020.01.001","journal-title":"Ann. Endocrinol."},{"key":"3916_CR27","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1002\/clc.23352","volume":"43","author":"SYH Falhammar H","year":"2020","unstructured":"S.Y.H. Falhammar H, Clinical features, complications, and outcomes of exogenous and endogenous catecholamine-triggered Takotsubo syndrome: A systematic review and meta-analysis of 156 published cases. Clin. Cardiol. 43, 459\u2013467 (2020). https:\/\/doi.org\/10.1002\/clc.23352","journal-title":"Clin. Cardiol."},{"key":"3916_CR28","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1002\/mgg3.313","volume":"5","author":"WHW Chew","year":"2017","unstructured":"W.H.W. Chew, E. Courtney, K.H. Lim, S.T. Li, Y. Chen, M.H. Tan et al. Clinical management of pheochromocytoma and paraganglioma in Singapore: missed opportunities for genetic testing. Mol. Genet. Genom. Med. 5, 602\u2013607 (2017). https:\/\/doi.org\/10.1002\/mgg3.313","journal-title":"Mol. Genet. Genom. Med."},{"key":"3916_CR29","doi-asserted-by":"publisher","unstructured":"P. Iglesias, E. Santacruz, P. Garcia-Sancho, A.P. Marengo, F. Guerrero-Perez, H. Pian et al. Pheochromocytoma: A three-decade clinical experience in a multicenter study. Rev. Clin. Esp. (2021). https:\/\/doi.org\/10.1016\/j.rceng.2019.12.011","DOI":"10.1016\/j.rceng.2019.12.011"},{"key":"3916_CR30","doi-asserted-by":"publisher","first-page":"220091","DOI":"10.1530\/EO-22-0091","volume":"3","author":"JV Lima Jr.","year":"2023","unstructured":"J.V. Lima Jr., N.M. Scalissi, K.C. de Oliveira, S.C. Lindsey, C. Olivati, E.N. Ferreira et al. Germline genetic variants in pheochromocytoma\/paraganglioma: Single-center experience. Endocr. Oncol. 3, 220091 (2023). https:\/\/doi.org\/10.1530\/EO-22-0091","journal-title":"Endocr. Oncol."},{"key":"3916_CR31","doi-asserted-by":"publisher","first-page":"2100251","DOI":"10.1200\/PO.21.00251","volume":"6","author":"MD Colton","year":"2022","unstructured":"M.D. Colton, K. Tompkins, E. O'donnell, D. Aisner, C.H. Lieu, E.Q. Konnick et al. Case of metastatic pheochromocytoma and meningiomas in a patient with lynch syndrome. JCO Precis Oncol. 6, 2100251 (2022). https:\/\/doi.org\/10.1200\/PO.21.00251","journal-title":"JCO Precis Oncol."},{"key":"3916_CR32","doi-asserted-by":"publisher","first-page":"102015","DOI":"10.1016\/j.eucr.2022.102015","volume":"42","author":"KM Rodriguez","year":"2022","unstructured":"K.M. Rodriguez, K.T. Harris, N. Singla, Adrenal pheochromocytoma in a patient with Lynch Syndrome. Urol. Case Rep. 42, 102015 (2022). https:\/\/doi.org\/10.1016\/j.eucr.2022.102015","journal-title":"Urol. Case Rep."},{"key":"3916_CR33","doi-asserted-by":"publisher","DOI":"10.1186\/s12893-020-00824-6","volume":"20","author":"SQ Fu","year":"2020","unstructured":"S.Q. Fu, S.Y. Wang, Q. Chen, Y.T. Liu, Z.L. Li, T. Sun, Laparoscopic versus open surgery for pheochromocytoma: A meta-analysis. BMC Surg. 20, 167 (2020). https:\/\/doi.org\/10.1186\/s12893-020-00824-6","journal-title":"BMC Surg."},{"key":"3916_CR34","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1097\/JS9.0000000000000390","volume":"109","author":"J Wang","year":"2023","unstructured":"J. Wang, Q. Liu, S. Jiang, J. Zhang, J. He, Y. Li et al. Preoperative alpha-blockade versus no blockade for pheochromocytoma-paraganglioma patients undergoing surgery: A systematic review and updated meta-analysis. Int. J. Surg, 109, 1470\u20131480 (2023). https:\/\/doi.org\/10.1097\/JS9.0000000000000390","journal-title":"Int. J. Surg,"},{"key":"3916_CR35","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1530\/EC-17-0321","volume":"7","author":"H Falhammar","year":"2018","unstructured":"H. Falhammar, M. Kjellman, J. Calissendorff, Initial clinical presentation and spectrum of pheochromocytoma: a study of 94 cases from a single center. Endocr. Connect. 7, 186\u2013192 (2018). https:\/\/doi.org\/10.1530\/EC-17-0321","journal-title":"Endocr. Connect."},{"key":"3916_CR36","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41440-019-0339-y","volume":"43","author":"M Parasiliti-Caprino","year":"2020","unstructured":"M. Parasiliti-Caprino, B. Lucatello, C. Lopez, J. Burrello, F. Maletta, M. Mistrangelo et al. Predictors of recurrence of pheochromocytoma and paraganglioma: A multicenter study in Piedmont, Italy. Hypertens. Res. 43, 500\u2013510 (2020). https:\/\/doi.org\/10.1038\/s41440-019-0339-y","journal-title":"Hypertens. Res."},{"key":"3916_CR37","doi-asserted-by":"publisher","unstructured":"A. Parente, S.K. Kamarajah, J.P. Thompson, C. Crook, S. Aspinall, R. Melvin, et al. Risk factors for postoperative complications after adrenalectomy for phaeochromocytoma: multicentre cohort study. BJS Open. 7 (2023). https:\/\/doi.org\/10.1093\/bjsopen\/zrad090","DOI":"10.1093\/bjsopen\/zrad090"},{"key":"3916_CR38","doi-asserted-by":"publisher","first-page":"1279828","DOI":"10.3389\/fendo.2023.1279828","volume":"14","author":"M Araujo-Castro","year":"2023","unstructured":"M. Araujo-Castro, I. Garc\u00eda Sanz, C. M\u00ednguez Ojeda, F. Hanzu, M. Mora, A. Vicente et al. Local recurrence and metastatic disease in pheochromocytomas and sympathetic paragangliomas. Front. Endocrinol. 14, 1279828 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1279828","journal-title":"Front. Endocrinol."},{"key":"3916_CR39","doi-asserted-by":"publisher","first-page":"1121397","DOI":"10.3389\/fendo.2023.1121397","volume":"14","author":"T Su","year":"2023","unstructured":"T. Su, Y. Yang, L. Jiang, J. Xie, X. Zhong, L. Wu et al. SDHB immunohistochemistry for prognosis of pheochromocytoma and paraganglioma: A retrospective and prospective analysis. Front. Endocrinol. 14, 1121397 (2023). https:\/\/doi.org\/10.3389\/fendo.2023.1121397","journal-title":"Front. Endocrinol."},{"key":"3916_CR40","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1038\/s41574-023-00926-0","volume":"20","author":"D Ta\u00efeb","year":"2023","unstructured":"D. Ta\u00efeb, S. N\u00f6lting, N.D. Perrier, M. Fassnacht, J.A. Carrasquillo, A.B. Grossman et al. Management of phaeochromocytoma and paraganglioma in patients with germline SDHB pathogenic variants: An international expert Consensus statement. Nat. Rev. Endocrinol. 20, 168\u2013184 (2023). https:\/\/doi.org\/10.1038\/s41574-023-00926-0","journal-title":"Nat. Rev. Endocrinol."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03916-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-024-03916-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-024-03916-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,1]],"date-time":"2024-10-01T01:39:00Z","timestamp":1727746740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-024-03916-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,8]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,10]]}},"alternative-id":["3916"],"URL":"https:\/\/doi.org\/10.1007\/s12020-024-03916-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3890993\/v1","asserted-by":"object"}]},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,8]]},"assertion":[{"value":"23 January 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}